

Human IL-22 Recombinant Protein Carrier-Free

Catalog Number: 34-8229

Also Known As: Interleukin-22, IL22

RUO: For Research Use Only. Not for use in diagnostic procedures.

Product Information

Contents: Human IL-22 Recombinant Protein Carrier-Free

REF **Catalog Number:** 34-8229

Handling Conditions: For best recovery, quick-spin vial prior to opening. Use in sterile environment.

Source: E. coli expressed amino acids Ala34-Ile179 of mature human IL-22 accession # NM_020525

Molecular Mass: The protein is not methionylated at the N-terminal and has a predicted molecular mass of 16,880. The DTT reduced protein migrates as a 15 kDa polypeptide on SDS-PAGE. The non-reduced protein migrates as a 13 kDa polypeptide.

Purity: > 98% as determined by SDS-PAGE.

Endotoxin Level: Less than 0.01 ng/ug cytokine as determined by the LAL assay.

Bioactivity: Measured by induction of IL-10 production by Colo205 cells. The ED50 for this is typically below 100 pg/mL, corresponding to a specific activity of greater than 1.0 x 10e7 U/mg.

Formulation: Sterile liquid; 10 mM sodium phosphate, 0.3 M NaCl, pH 7.2. 0.22 um filtered.



Temperature Limitation: Store at less than or equal to -70°C.



Batch Code: Refer to Vial



Use By: Refer to Vial

Description

IL-22, also known as IL-10-related T-cell derived inducible factor, is an alpha helical cytokine and is considered a member of the IFN-IL-10 family, which includes IL-19, IL-20, IL-24, IL-26, IL-28, IL-29, and the type I and II interferons. IL-22 is produced mainly by activated T and NK cells. No other immune cells (resting or activated) or non-immune cells have been found to produce IL-22. Amongst the T cells, in mice Th1 and Th17 cells appear to be the primary producers of IL-22. IL-22 acts by engaging the heterodimeric receptor complex consisting of primary receptor IL-22R1 and accessory receptor IL-10R2. IL-22R1 also binds IL-20 and IL-24; IL-10R2 also binds IL-10, IL-27, IL-28, and IL-29. Binding of IL-22 to its receptor complex induces signal transduction, particularly via the JAK-STAT pathway. In addition to the cell surface IL-22R1/IL-10R2 complex, a soluble single chain IL-22 receptor termed IL-22BP has been found to antagonize IL-22 binding and signaling. IL-22 appears not to directly influence immune cells; major targets of the cytokine appear to be nonimmune cells, such as cells of the skin, digestive and respiratory system, as well as hepatocytes, and keratinocytes.

IL-22 has been described as an effector cytokine of the Th17 lineage. Along with IL-17A and IL-17F, IL-22 regulates genes associated with innate immunity of the skin. IL-17A, IL-17F and IL-22 are all coexpressed by Th17 cells, however, differentially regulated. Note that TGFb, which is required for IL-17A production, inhibits IL-22 production. The effects of IL-22 include induction of acute phase reactants and antimicrobial proteins, as well as increasing the mobility of keratinocytes. IL-22 has been reported to mediate IL-23-induced acanthosis and dermal inflammation through activation of Stat3.

Applications Reported

The recombinant human IL-22 has been reported useful for bioassay.

Applications Tested

This recombinant IL-22 has been tested in bioassay for induction of IL-10 production by Colo205 cells. The ED50 for this effect is typically below 100 pg/ml, corresponding to a specific activity of greater than 1.0 x 10E7 U/mg.

References

- Liang, S.C., et al. 2006. IL-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. *J. Exp. Med.* 203: 2271-2279.
- Wolk, K., et al. 2007. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. *J. Immunol.* 178: 5973-5981.
- Zheng, Y., et al. 2007. IL-22, a Th17 cytokine, mediates IL-23 induced dermal inflammation and acanthosis. *Nature.* 445: 648-651.

